新華錦(600735.SH):日本全資子公司共生會擬向養老健康公司增資6400萬元
格隆匯11月26日丨新華錦(600735.SH)公佈,公司為更好滿足養老大健康業務發展需要,同時提高境外資金使用效率,公司的日本全資子公司一般財團法人TOMONIYIKIRU會(簡稱“共生會”)擬向公司子公司養老健康公司增資1000萬美元(摺合人民幣約6400萬元),以補充養老健康公司拓展業務亟需的流動資金。
本次對養老健康公司進行增資,有利於滿足其國內業務發展所需要的流動資金需求,可以提升自身運營能力,開發新的養老項目,拓展公司養老大健康業務。同時,本次增資事項有利於提高上市公司境外資金使用效率,提升公司整體運營效率和盈利水平,符合公司發展戰略和全體股東利益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.